ClinicalTrials.gg
CompletedNCT06571591CT-L03Updated May 15, 2026

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

A Phase 3 interventional study of CT-L03 Group 1 and CT-L03 Group 2 in T2DM, sponsored by Celltrion. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Celltrion · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
606
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.

02

Conditions studied

  • T2DM
03

In context

Lead sponsor

Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults at the time of signing the Form (ICF)
  • Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study
  • Diagnosed with T2DM

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with other types of diabetes than T2DM
  • History of reaction to the components or drugs of the same class as the IP or the background therapy
  • Uncontrolled severe complications of diabetes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
606 participants (actual)

Study arms

  • Active comparator
    Group 1

    Drug: CT-L03 Group 1 · Drug: Empagliflozin · Drug: Metformin

  • Active comparator
    Group 2

    Drug: CT-L03 Group 2 · Drug: Empagliflozin · Drug: Metformin

  • Placebo comparator
    Placebo

    Drug: Placebo · Drug: Empagliflozin · Drug: Metformin

Interventions

  • DrugCT-L03 Group 1

    tablets, QD, oral administration

  • DrugCT-L03 Group 2

    tablets, QD, oral administration

  • DrugPlacebo

    tablets, QD, oral administration

  • tablet, QD, oral administration

  • tablets, oral administration

06

What researchers measure

Primary outcomes

  1. HbA1c

    Change from Baseline in HbA1c

    Time frame: Week 24 of the Treatment

Secondary outcomes

  1. HbA1c

    Change from Baseline in HbA1c

    Time frame: Week 12 of the Treatment

  2. FPG

    Change from Baseline in fasting plasma glucose

    Time frame: Week 12 and 24 of the Treatment

  3. Body weight

    Change from Baseline in body weight

    Time frame: Week 12 and 24 of the Treatment

07

Study locations

1 site
  • Celltrion
    Incheon, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Apr 2026, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 26, 2024
StartActual
Aug 27, 2024
Primary completionActual
Apr 16, 2026
CompletionActual
May 4, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06571591
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Aug 27, 2024
Primary completion
Apr 16, 2026
Completion
May 4, 2026
Last update
May 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion